keep it here. don't miss of that. "fast money" is coming up. melissa lee, it's wwe today. >> it's starting its own online channel. we'll talk to the cfo of wwe. this talk about wrestling, we have wondering if we had wrestling names, what would they be? >> i'll tweet you some suggestions. >> yours, kelly, would be -- drum roll -- lush frost. >> it sounds like a nice paint color. >> over to you guys. >> all right, thanks. "fast money" starts right now. i'm melissa lee. here's tonight's lineup. target's credit card breech gets worse. a buying opportunity for investors? tesla shares getting burned

on the company wall chargers. plus the biotech stock that won't quit, up 500%. we got a top analyst to tell you which company could be the next intercept. let's get straight to our top story a confused market, the s&p and nasdaq ended the day higher the dow slid. 74,000 new adds. so, if today's muted action is any indication is no longer on jobs, where should investors be looking to next? >> i think confused is actually the right word for this market here, earlier in the week, i got short the s&p market. the market was getting a little fearful that things could get too hot and the fed would tapper too quickly. i think that's wrong. i think the fed is going to be on their tapper.

i think anything that popped up on that taper, i think you stay short. emerging markets, gold, stuff like that, that's where you want to stay short. >> the e kwekty really showed some concern over the jobs numbers. maybe weather was the problem or it was too noisy. >> it was a very noisy number. i think this number is more of a anolmy. everybody was rushing to upside. i think that's all is still true. if you're a buyer of gold today, you should prepared that gold is going to get knocked down when the fed comes in and does another 10 billion, that's exactly the prom. you can't ashum that anything has changed today. i'm an emerging markets guy. >> i hear -- i agree with timmy,

it's probably an anolamy. some of these retailers, some terrible numbers out there. maybe it's not i think the real economy is saying one thing and i think the stock market is saying something else. earlier today, i said the channel between the two would be bigger. tonight, we have engelbert hum per dink. >> i went rummaging around the nasdaq to see if i could find a tie. i said, melissa, i got a tie, and in fact, i brought out this one. >> i said, absolutely not. >> leave knit the closet. off we go. we're tieless. >> the story behind it. >> on the s&p, we have been

waiting for the sell-off and it never seems to come. when you look at earnings, next week, we'll hear from the financials. i can't imagine they'll give us anything to sell the markets. i would say if you're looking for this sell-off, you're more likely to get it in february or march versus next week, although technically the market does seem a little bit soft. >> let's get to some unusual activity here. dr. jay joining us on the fast line for details on this trade. >> yeah, me police sa, there's a stock line, they got a ruling abouts asbestos liability just t the bell today. someone may have been tipped off before that. before that, they traded 15 times the numbers of calls. 60 calls and 65 calls. which are exploding in value as

the stock trades to $75 in the afterhours. closed at 59, melissa. >> thank you for keeping us post. jon najarian. meantime, let's get to shares of intercept pharmaceuticals. up a whopping 500%. ci citigroup putting out a number today, upping its price target to $400 a share. joining us the head of citi's biotech division. is it overvalued at this point. >> what we said in the notes, the mates are conservative. we're talking about a disease that affects about 10% of the u.s. population, 600,000

patients have to get treated. data is phenomenally good. >> you mentioned about 10% to 15% of the population in the united states has early staging s of this particular disease, at the same time, you said that the number of addressable patients is unknown, how is that possible? >> no one knows what causes the disease overall, it looks like it's related to diabetes, a metabolic problem. again, we're talking about 30 million, maybe 6 million, 600 at least has to get treated. that's 30 billion right there. >> to mel's point, it seems like a small number of patients, is there something else, another disease that this drug could be used for? >> this was expected. they're developing this drug for another autoimmune disease,

related to the liver, that data is coming in the second quarter. that data is expected to next quarter. this study was stopped early based on phenomenal results. >> do they have another drug in the pipeline? >> they have two other products that are earlier stage. this drug is also being developed for blood pressure of the liver. >> so, at this point, the stock is above your raise, sharply raise target, would you say it's still a buy? >> what we can say at this point, we continue to have a buy rating. . the sales estimates are conservative at this point. distinctly stated in the note. if gets to the market, they're going to take more than 30%. >> could it be a takeout candidate or it's offlimits to

some of the pharm companies. >> we're talking about a multimillion-dollar opportunity. this is exactly what companies need. not a lot of companies fully own their product. this is one of them. we have 5 million based on 30%. if it gets to the market it should be more than 30%. >> when you see a stock do this, more often or not, it makes you look at competitors or someone else in the field have the same effect? if we could back a couple of days we would know what to do with our life savings. anything in your work to mirror this to the slightest extreme? >> nothing has worked in this disease. many have tried to stop this study early. based on this phenomenal result that you haven't seen very often. early data translates into

blockbusters. we're talking about beating estimates. i'm thinking it's going to do $4 billion to $6 billion. we have seen it before. >> all right, stay right there. because he's going to give does company who could be the next intercept pharmaceutical stock. the smackdown, the wwe is creating a video game channel. the cfo of wwe joins us live after this break. >> nice move. 2009. on the u.s.s. saratoga in 1982. [ male announcer ] once it's earned, usaa auto insurance is often handed down from generation to generation. because it offers a superior level of protection. and because usaa's commitment to serve current and former military members and their families is without equal. begin your legacy. get an auto insurance quote.

usaa. we know what it means to serve. make it happen with fidelity active trader pro. it's one more innovative reason serious investors are choosing fidelity. call or click to open your fidelity account today. so ally bank has a that won't trap me in a rate. that's correct. cause i'm really nervous about getting trapped. why's that? uh, mark? go get help! i have my reasons. look, you don't have to feel trapped with our raise your rate cd. if our rate on this cd goes up, yours can too. oh that sounds nice.

don't feel trapped with the ally raise your rate cd. ally bank. your money needs an ally.

i just knew from the get-go that i was... flat out getting a good deal. when you're ready to buy a car, save time, save money, and never overpay. visit truecar.com ♪ we mentioned a huge move in intercept pharmaceuticals, climbing more than 500% in the past two days. could there be another intercept pharmaceutical. let's bring back doctor, what is it in your view. >> the next in our view is clovis, clvs. manage system very well known to the street, they have sold two

other companies previously in the field. they got three drugs. . the first one and we care about the most is their lung cancer product, we're expecting a lot of data over -- starting next week at an industry conference. we think the market's about 400 billion. this drug is better than what's out there and the two drugs that are out there are selling 2.5 billion. we think it's going to be even better. patients aren't going to get resistant. >> clvs is your next potential. at the conference, lot of companies are going to be out there, what is the company that you'll be watching closely? >> the most important one, is salgene. they're going to be reporting next week. we're way above consensus for

earnings. we think they're going to guide pretty well. more importantly, what they're going to do for the next three years to 2017, the next outlook they can raise estimates. clovis, early december with jpmorgan that was interesting. you heard the doctor on celgene i agree. time for the top trades today. first up target out with an upit is on its investigation on the data breech. it includes the names, mailing addresses or e-mail addresses for up to 110 million. same-store sales fell 6%. >> it gets worse. is it tradeable? >> i say yes.

62 is where it held. it bounced from there. seemingly have held it again. we're trading 62.5, that seems to be the line in the sand, i think risk/reward for the trade, again 62, target is a long side buy. >> for monday, becky quick sits down for a squawk box exclusive at 6:00 a.m. eastern time. coming up next -- tesla shares getting hit today after the company confirmed it will update its wall charger adapters. >> you know, what's going on here with the battery fires with the potential garage fires, is not the story with tesla, you're talking about a gen 3. genx said to me it's no to a

2015 story, it's probably a 2016 story. battery costs are going to be a major hurdle to the markets here. you don't need to buy it. you don't sell it hard on this news today. >> i actually like tesla, they're going to change whatever they need to change and it's against 145, the area of support, so, i like it and i also like the fact -- >> you can like the stock, but a house fire is a lot more troublesome. >> the fire of the car on the road. >> i understand. >> it's more troublesome than that. >> you know what no one's sleeping a floor above that. >> okay, so -- >> today's event is a noneffect. not a reason to sell or buy tesla. it's about a valuation, a

company that's overhyped. last up here, blackberry bouncing back into the green after it upgraded the handset maker. it expects management to improve liquidity and strengthen the balance sheet. >> i have been in and out of blackberry, if they start focusing on that whole generation keyboard and security, i think they might have something there. >> all right, coming soon to a computer near you, huge muscles and oiled-up skin. the wwe launching subscription-only online ved owe channel next month, will it good for their bottom line? guy adami, loathsome spartan.

the last one we came one on our soehn stone cold steve grasso. >> nice, very nice. >> it's idea generation. it's all about giving you a framework on how to look at the market. the world has changed our show has evolved. >> i'm guy adami. i am fast money. >> i pete najarian. i am fast money. if you're living with moderate to severe crohn's disease, and it feels like your life revolves around your symptoms, ask your gastroenterologist about humira adalimumab. humira has been proven to work for adults who have tried other medications but still experience the symptoms of moderate to severe crohn's disease. in clinical studies, the majority of patients on humira saw significant symptom relief, and many achieved remission.

humira can lower your ability to fight infections, including tuberculosis. serious, sometimes fatal events, such as infections, lymphoma, or other types of cancer, have happened. blood, liver and nervous system problems, serious allergic reactions, and new or worsening heart failure have occurred. before starting humira, your doctor should test you for tb. ask your doctor if you live in or have been to a region where certain fungal infections are common. tell your doctor if you have had tb, hepatitis b, are prone to infections, or have symptoms such as fever, fatigue, cough, or sores. you should not start humira if you have any kind of infection. ask your gastroenterologist about humira today. remission is possible.

before you settle for another ordinary mattress, isn't it time you discovered the sleep number bed? the only bed clinically proven to relieve back pain and improve sleep quality. and right now, it's our lowest prices of the season. save $300 to $800 on our newest innovations. plus, 18-month special financing on all sleep number beds. only at a sleep number store, where queen mattresses start at just $699.99. sleep number. comfort individualized. of the dusty basement at 1406 35th street the old dining table at 25th and hoffman. ...and the little room above the strip mall off roble avenue. ♪ this magic moment it is the story of where every great idea begins. and of those who believed they had the power to do more. dell is honored to be part of some of the world's great stories. that began much the same way ours did. in a little dorm room -- 2713.

♪ this magic moment ♪ take a look at the shares of clovis, up 20% in the after-hour trading. after it was said it's their under the radar pick. >> not under the radar anymore. it's a friday night smackdown, world wrestling entertainment announced the launch of video onlines.

chief strategy of world wrestling federation, george barrios. what does this do to your pay per view subscribers. it seems like you're essentially going to cut them out because the pricing is such a steep discount. >> yeah from our perspective, melissa, we start every question within the company, how do we drive for value for our consumers and our audience and how do we put smiles on their face? the ww network is about that, taking our most valuable content, for all 12 events, people will be able to get that live, $9.99 a month. original programming. new reality series. including every wwe and ecw pay

per view for $9.99. it brings a lot of value. and we have told our distribution partners that we'll continue to provide pay per view to them if they want to bring that to their customers. >> you realize that i i mean, customers will pay $55 or $70 for a live pay per view when they can just pay 9.95 for your subscription. you're severely undercutting your partners, you may want to be in business with them but you're eshgtively cutting them out. >> we like to think about it at customer first. we're really excited. it's a global plat form. not only can we domestically, we have plans to go to uk, the nor deck, knnew zealand, australia. it's a great day for wwe and our customers. >> so, will it be a creative and

when? >> two things will drive potentially tripling of our 2012 profits, number one the launch of the network and the second one is the renewal of our four largest content agreement. we're bringing live content into the marketplace. in the u.s. as you know that has become the coin of the realm for networks. live viewership is at an absolute premium, we're thrilled to have those 260 hours in the marketplace coming up. our deals in the uk and india are up as well. getting into the range of 120. >> george, a pleasure speaking with you. thank you for your time. >> well, in the same these guys are fantastic promoting of their products, this sounds like the promotion of a network, they say

62% of american households have some affinity for wwe-type products. the expectations that people have and the assertion they're going to double or triple, that's a little scary for me after the move in this stock. as much as i was -- i'm not buying this one. i'm sorry. time now for pops and drops. big movers of the day. dropping tiffany's 2%. >> holiday sales came in up 4%. which i think was very good. this, to me, is one of the great global luxury names and you should be buying weakness in this. >> terrible earnings here, missed on earnings, alcoa. >> abercrombie and fitch. >> they're comps were lousy.

i say you stay long on this stock. $36 on the downside. >> chevron dropped down 2%. grasso? >> a series of highs and lows and it looks poise to really break out here. i would say bounce -- not break out -- but to bounce. the consensus is negative on the stock. >> we got to drop here for fake tans. pop icon paula abdul filed a personal injury lawsuit against a tanning salon, saying she suffered severe burns after the tan. an infrared body wrap was apply wrongly. >> guys, you have that issue? >> infrinfrared body wraps.

>> i'm half-italian, half-sicilian. time now for the final trade. >> oil. been down a lot. >> grasso? >> petroleum. >> what is your wrestling name. >> honey bomb shell. that does it for us. see you next monday at 5:00. s biggest questions. like, if you could save hundreds on car insurance by making one simple call, why wouldn't you make that call? see, the only thing i can think of is that you can't get any... bars. ah, that's better. it's a beautiful view. i wonder if i can see mt. rushmore from here. geico. fifteen minutes could save you fifteen percent or more on car insurance.

♪ this is "options action." tonight, just buy it. we'll try the sell-off in retailers could spell pain for nike. pizza, pizza. why are so many fast-food companies fighting other money. and telephone trouble. >> no! >> despite the smartphone revolution, we'll tell you why it might be time to hang up on telecom